Bank of New York Mellon
COCP icon

Bank of New York Mellon’s Cocrystal Pharma COCP Stock Holding History

Bank of New York Mellon’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,710
Closed -$13K – 4481
2022
Q3 		$13K Hold
3,710
– – ﹤0.01% 4485
2022
Q2 		$18K Hold
3,710
– – ﹤0.01% 4504
2022
Q1 		$24K Hold
3,710
– – ﹤0.01% 4608
2021
Q4 		$29K Hold
3,710
– – ﹤0.01% 4558
2021
Q3 		$47K Hold
3,710
– – ﹤0.01% 4440
2021
Q2 		$56K Hold
3,710
– – ﹤0.01% 4311
2021
Q1 		$62K Sell
3,710
-402
-10% -$8.16K ﹤0.01% 4228
2020
Q4 		$67K Buy
+4,112
New +$57.1K ﹤0.01% 4124

Other funds holding COCP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon's COCP Position: Q4 2022 in Review

Bank of New York Mellon sold out of Cocrystal Pharma (COCP) in Q4 2022, closing a stake of 3,710 shares — an estimated $13K sold.

Bank of New York Mellon first reported a position in COCP in Q4 2020 and held it in 8 quarters. The position peaked at $67K in Q4 2020. 21 funds tracked by Wall St. Rank hold COCP as of Q4 2022.

  • Bank of New York Mellon reported no remaining Cocrystal Pharma position as of Q4 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 3,710 Cocrystal Pharma shares in Q4 2022, an estimated $13K.
  • Bank of New York Mellon first reported a position in Cocrystal Pharma in Q4 2020 and held it in 8 quarters.
  • Bank of New York Mellon's Cocrystal Pharma position peaked at $67K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.